Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
15 hedge funds and large institutions have $4.06M invested in Timber Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
17% less funds holding
Funds holding: 18 → 15 (-3)
48% less capital invested
Capital invested by funds: $7.8M → $4.06M (-$3.74M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.22M |
| 2 |
AC
Armistice Capital
New York
|
+$630K |
| 3 |
Millennium Management
New York
|
+$98.1K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$8.18K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$2.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$171K |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$54.5K |
| 3 |
VF
Virtu Financial
New York
|
-$43K |
| 4 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
-$17K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9K |
TMBR Hedge Fund Activity: Q4 2017 in Review
15 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q4 2017, worth a combined $4.06M — down 48% from $7.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TMBR and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.22M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $171K sold.
- 15 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q4 2017, down from 18 in Q3 2017.
- Funds reported $4.06M of Timber Pharmaceuticals, Inc. stock for Q4 2017, down 48% quarter-over-quarter.
- 3 funds opened new Timber Pharmaceuticals, Inc. positions in Q4 2017 and 6 closed out, a net change of -3 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q4 2017 was Sabby Management, an estimated $1.22M added.
- The largest Timber Pharmaceuticals, Inc. seller in Q4 2017 was Baker Bros. Advisors, an estimated $171K sold.
Based on aggregated 13F filings for Q4 2017.